Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer

Final scope TA621 (PDF 353 KB)

Draft scope and provisional stakeholder list comments table (post-referral) TA621 (PDF 201 KB)

Committee papers ACD from TA621 (PDF 273 KB)

Committee papers ACD papers from TA621 (PDF 8.02 MB)

Committee papers FAD from TA621 (PDF 2.2 MB)

Committee papers FAD papers from TA621 (PDF 263 KB)

Final draft guidance

Final appraisal document (PDF 288 KB)

Public committee slides (PDF 649 KB)